phosphatidylcholines has been researched along with camptothecin in 18 studies
| Studies (phosphatidylcholines) | Trials (phosphatidylcholines) | Recent Studies (post-2010) (phosphatidylcholines) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
|---|---|---|---|---|---|
| 32,204 | 443 | 5,593 | 13,002 | 2,229 | 5,391 |
| Protein | Taxonomy | phosphatidylcholines (IC50) | camptothecin (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
| Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Burke, TG; Gao, X | 1 |
| Burke, TG; Mishra, AK; Wall, ME; Wani, MC | 1 |
| Anthony, ML; Brindle, KM; Zhao, M | 1 |
| Gilbert, BE; Knight, V; Koshkina, NV; Seryshev, A; Waldrep, JC | 1 |
| Gilbert, BE; Giovanella, BC; Kleinerman, ES; Knight, V; Koshkina, NV; Waldrep, JC | 1 |
| Ahmad, I; Parmar, M; Peikov, V; Ugwu, S; Zhang, A | 1 |
| Fang, XL; Li, JC; Sha, XY; Zhang, LJ | 1 |
| Chen, J; Chu, XZ; Guo, JX; Ping, QN; Song, MM | 1 |
| Cabral-Lilly, D; Cafiso, DS; Cho, C; Dicko, A; Ellena, JF; Frazier, AA; Hinderliter, A; Liboiron, BD; Mayer, LD; Tardi, PG; Weber, T; Xie, X | 1 |
| Gaud, R; Shende, P | 1 |
| Atyabi, F; Dinarvand, R; Esmaeili, F; Farkhondehfai, A | 1 |
| Anantha, M; Bally, M; Patankar, N; Ramsay, E; Waterhouse, D | 1 |
| Li, P; Lin, Y; Ran, H; Ren, J; Tan, J; Wang, Z; Zhang, Q; Zheng, Y | 1 |
| Anderson, BD; Modi, S; Xiang, TX | 1 |
| Aljuffali, IA; Fang, JY; Huang, YJ; Sung, CT; Wen, CJ | 1 |
| Anantha, M; Bally, MB; Harasym, N; Manisali, I; Masin, D; Osooly, M; Ostlund, C; Santos, ND; Strutt, D; Sutherland, BW; Waterhouse, DN; Webb, MS; Wehbe, M | 1 |
| Du, Y; He, W; Li, X; Yao, C; Zhou, W | 1 |
| Chakraborty, K; Hu, W; Kang, M; Loverde, SM; Tang, PK | 1 |
18 other study(ies) available for phosphatidylcholines and camptothecin
| Article | Year |
|---|---|
Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine.
Topics: Antineoplastic Agents; Buffers; Camptothecin; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Drug Carriers; Drug Stability; Humans; Hydrogen-Ion Concentration; Lactones; Liposomes; Phosphatidylcholines; Topotecan | 1994 |
Lipid bilayer partitioning and stability of camptothecin drugs.
Topics: Binding Sites; Camptothecin; Dimyristoylphosphatidylcholine; Drug Stability; Fluorescence Polarization; Hydrogen-Ion Concentration; Kinetics; Lipid Bilayers; Phosphatidylcholines; Phosphatidylglycerols; Spectrometry, Fluorescence; Spectrophotometry; Structure-Activity Relationship | 1993 |
Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells.
Topics: Alkaloids; Apoptosis; Benzophenanthridines; Camptothecin; Choline; Cytidine Diphosphate Choline; Diacylglycerol Cholinephosphotransferase; Enzyme Inhibitors; Etoposide; Farnesol; Flow Cytometry; HL-60 Cells; Humans; Hydrogen-Ion Concentration; Phenanthridines; Phosphatidylcholines; Phosphorylcholine | 1999 |
Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice.
Topics: Aerosols; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Carriers; Female; Humans; Injections, Intramuscular; Liposomes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Phosphatidylcholines | 1999 |
9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice.
Topics: Aerosols; Animals; Antineoplastic Agents; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Microscopy, Electron; Osteosarcoma; Particle Size; Phosphatidylcholines; Xenograft Model Antitumor Assays | 2000 |
pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cardiolipins; Cholesterol; Chromatography, Gel; Diphenylhexatriene; Fluorescence Polarization; Fluorescent Dyes; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Irinotecan; Lipid Bilayers; Liposomes; Particle Size; Phosphatidylcholines; Temperature; Topoisomerase I Inhibitors | 2005 |
[9-nitrocamptothecin nanostructured lipid carrier system: in vitro releasing characteristics, uptake by cells, and tissue distribution in vivo].
Topics: Animals; Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Female; Hexoses; Liver; Lung; Macrophages, Peritoneal; Mice; Nanoparticles; Particle Size; Phagocytosis; Phosphatidylcholines; Polyethylene Glycols; Tissue Distribution | 2005 |
Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cholesterol; Drug Compounding; Feasibility Studies; Glycine max; Hydrogenation; Injections, Intravenous; Liposomes; Male; Particle Size; Phosphatidylcholines; Rats; Rats, Sprague-Dawley; Solubility | 2006 |
Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Calorimetry; Camptothecin; Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Cholesterol; Copper; Drug Carriers; Drug Compounding; Excipients; Floxuridine; Gluconates; Irinotecan; Liposomes; Magnetic Resonance Spectroscopy; Microscopy, Electron, Transmission; Phosphatidylcholines; Phosphatidylglycerols; Solubility; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 2008 |
Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Chitosan; Cholesterol; Chromatography, High Pressure Liquid; Drug Carriers; Drug Compounding; Drug Stability; Electrochemistry; Freeze Fracturing; Gelatin; Irinotecan; Liposomes; Phosphatidylcholines | 2009 |
Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Drug Stability; Female; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Particle Size; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Solubility; Technology, Pharmaceutical; Tissue Distribution | 2009 |
The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™.
Topics: Animals; Antineoplastic Agents; Calcimycin; Camptothecin; Cell Membrane Permeability; Chemistry, Pharmaceutical; Cholesterol; Chromatography, High Pressure Liquid; Copper; Female; Ionophores; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Phosphatidylcholines | 2011 |
Ultrasound triggered drug release from 10-hydroxycamptothecin-loaded phospholipid microbubbles for targeted tumor therapy in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Male; Mice; Microbubbles; Neoplasms; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Sonication; Tumor Burden | 2012 |
Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions.
Topics: Camptothecin; Drug Compounding; Hydrogen-Ion Concentration; Liposomes; Models, Theoretical; Organosilicon Compounds; Permeability; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Solubility; Solutions | 2012 |
Nanocomposite liposomes containing quantum dots and anticancer drugs for bioimaging and therapeutic delivery: a comparison of cationic, PEGylated and deformable liposomes.
Topics: Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Camptothecin; Cations; Cell Survival; Diagnostic Imaging; Drug Delivery Systems; Female; Irinotecan; Liposomes; Melanoma, Experimental; Mice; Mice, Nude; Nanocomposites; Particle Size; Phosphatidylcholines; Polyethylene Glycols; Quantum Dots; Spectrometry, Fluorescence; Static Electricity; Wound Healing | 2013 |
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cholesterol; Colon; Diarrhea; Disease Models, Animal; Drug Therapy, Combination; Female; Fluorouracil; Intestine, Small; Irinotecan; Liposomes; Nanoparticles; Phosphatidylcholines; Rats, Sprague-Dawley | 2014 |
Redox-sensitive dimeric camptothecin phosphatidylcholines-based liposomes for improved anticancer efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Drug Delivery Systems; Erythrocytes; Female; Humans; Liposomes; MCF-7 Cells; Mice; Mice, Inbred BALB C; Oxidation-Reduction; Phosphatidylcholines; Polymers | 2019 |
Interaction of Camptothecin with Model Cellular Membranes.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Membrane; Hydrophobic and Hydrophilic Interactions; Lipid Bilayers; Models, Molecular; Phosphatidylcholines | 2020 |